NLS-VPAC1 Technology Platform


NLS-VPAC1 imaging agent

Our NLS-VPAC1 imaging agent attaches to the surface of cells that contain large amounts of a biomarker called VPAC1. These cells are cancerous with the surrounding normal tissue possessing low levels of the VPAC1 biomarker protein.  Once attached to the cells, our imaging agent begins the second phase of its job. This imaging agent has a passenger attached, Copper-64.  This is a form of copper that is weakly radioactive, and as it decays, the imaging agent emits energy from the tumor to which it is bound. The energy is detected by a specialized camera, or what is commonly called a PET scanner. There are over 5,500 PET scanners in the United States being used in hospitals right now. This information is then transformed into a 3-dimensional image of the body that shows the exact size and location of only malignant tumors, not benign masses.

NLS-VPAC1 represents a huge leap over existing technologies by specifically visualizing cancer cells at the molecular level at early stages of disease.

  • Small peptide ligand to VPAC1 receptor attached to weakly emitting radioisotope (Copper-64)
  • Visualizes malignant tumors in breast, prostate and other cancers
  • Utilizes PET imaging



NLS-VPAC1 urine screen

NuView’s urine screen is designed to specifically detect prostate and bladder cancer cells that are released into the urinary tract.  This test uses the same molecule as the NLS-VPAC1 imaging tool, but replaces the Copper-64 passenger used for PET cameras, with a different passenger more appropriate for laboratory testing (a fluorophore).

Our NLS-VPAC1 urine screen is being developed to replace the inaccurate and controversial PSA test.

  • Small peptide ligand to VPAC1 receptor attached to fluorophore
  • Detects prostate and bladder cancer cells released into the urine
  • Standard testing methods completed in a laboratory


NuView has licensed this imaging biomarker from Mathew Thakur, PhD at Thomas Jefferson University and is developing NLS-VPAC1 to revolutionize the detection and diagnosis of breast, bladder and prostate cancers.  Dr. Thakur is a field leader, past President of the Society of Nuclear Medicine and Scientific Advisor of NuView.